162 related articles for article (PubMed ID: 2509390)
21. The Role of Efflux Pumps in Schistosoma mansoni Praziquantel Resistant Phenotype.
Pinto-Almeida A; Mendes T; Armada A; Belo S; Carrilho E; Viveiros M; Afonso A
PLoS One; 2015; 10(10):e0140147. PubMed ID: 26445012
[TBL] [Abstract][Full Text] [Related]
22. Schistosoma mansoni: stage-dependent damage after in vivo treatment with praziquantel.
Shaw MK
Parasitology; 1990 Feb; 100 Pt 1():65-72. PubMed ID: 2107508
[TBL] [Abstract][Full Text] [Related]
23. Schistosoma mansoni: In vivo evaluation of Phyllanthus amarus hexanic and ethanolic extracts.
de Oliveira CNF; Frezza TF; Garcia VL; Figueira GM; Mendes TMF; Allegretti SM
Exp Parasitol; 2017 Dec; 183():56-63. PubMed ID: 29074138
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of two praziquantel treatments among primary school children in an area of high Schistosoma mansoni endemicity, Nile Delta, Egypt.
Barakat R; El Morshedy H
Parasitology; 2011 Apr; 138(4):440-6. PubMed ID: 21078223
[TBL] [Abstract][Full Text] [Related]
25. Transcriptomic analysis of reduced sensitivity to praziquantel in Schistosoma mansoni.
Sanchez MC; Cupit PM; Bu L; Cunningham C
Mol Biochem Parasitol; 2019 Mar; 228():6-15. PubMed ID: 30658180
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic effect of subcurative dose praziquantel on Schistosoma mansoni infected mice and resistance to challenge infection after treatment.
Chaiworaporn R; Maneerat Y; Rojekittikhun W; Ramasoota P; Janecharut T; Matsuda H; Kitikoon V
Southeast Asian J Trop Med Public Health; 2005 Jul; 36(4):846-52. PubMed ID: 16295535
[TBL] [Abstract][Full Text] [Related]
27. Parasitological, hematological and ultrastructural study of the effect of COX-2 inhibitor, pyocyanin pigment and praziquantel, on S. mansoni infected mice.
Mohamed AH; Ezz El-Din N; Fahmy ZH; El-Shennawy AM; Hassan E
J Egypt Soc Parasitol; 2006 Apr; 36(1):197-220. PubMed ID: 16605111
[TBL] [Abstract][Full Text] [Related]
28. Niosomes for enhanced activity of praziquantel against Schistosoma mansoni: in vivo and in vitro evaluation.
Zoghroban HS; El-Kowrany SI; Aboul Asaad IA; El Maghraby GM; El-Nouby KA; Abd Elazeem MA
Parasitol Res; 2019 Jan; 118(1):219-234. PubMed ID: 30421348
[TBL] [Abstract][Full Text] [Related]
29. Parasitological and histo-pathological studies on schistosomiasis mansoni infected mice and treated with praziquatel and/or oltipraz.
Morsy GH
J Egypt Soc Parasitol; 2009 Aug; 39(2):687-701. PubMed ID: 19795775
[TBL] [Abstract][Full Text] [Related]
30. Effect of praziquantel treatment on lung-stage larvae of Schistosoma mansoni in vivo.
Flisser A; McLaren DJ
Parasitology; 1989 Apr; 98 Pt 2():203-11. PubMed ID: 2474788
[TBL] [Abstract][Full Text] [Related]
31. Schistosoma mansoni: larval damage and role of effector cell(s) in the synergy between vaccine immunity and praziquantel treatment.
Piper KP; Mott RF; Hockley DJ; McLaren DJ
Parasitology; 1991 Oct; 103 Pt 2():207-24. PubMed ID: 1660590
[TBL] [Abstract][Full Text] [Related]
32. In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel.
Liang YS; Coles GC; Doenhoff MJ; Southgate VR
Int J Parasitol; 2001 Sep; 31(11):1227-35. PubMed ID: 11513892
[TBL] [Abstract][Full Text] [Related]
33. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel.
Ismail M; Metwally A; Farghaly A; Bruce J; Tao LF; Bennett JL
Am J Trop Med Hyg; 1996 Aug; 55(2):214-8. PubMed ID: 8780463
[TBL] [Abstract][Full Text] [Related]
34. Use of fluorescent probes as a useful tool to identify resistant Schistosoma mansoni isolates to praziquantel.
Couto FF; Coelho PM; Araújo N; Kusel JR; Katz N; Mattos AC
Parasitology; 2010 Oct; 137(12):1791-7. PubMed ID: 20561394
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamics of mefloquine and praziquantel combination therapy in mice harbouring juvenile and adult Schistosoma mansoni.
el-Lakkany NM; el-Din SH; Sabra AN; Hammam OA
Mem Inst Oswaldo Cruz; 2011 Nov; 106(7):814-22. PubMed ID: 22124553
[TBL] [Abstract][Full Text] [Related]
36. Schistosoma mansoni: maturation rate and drug susceptibility of different geographic isolates.
Fallon PG; Mubarak JS; Fookes RE; Niang M; Butterworth AE; Sturrock RF; Doenhoff MJ
Exp Parasitol; 1997 May; 86(1):29-36. PubMed ID: 9149238
[TBL] [Abstract][Full Text] [Related]
37. Migration of the schistosomula of Schistosoma mansoni in mice vaccinated with radiation-attenuated cercariae, and normal mice: an attempt to identify the timing and site of parasite death.
Wilson RA; Coulson PS; Dixon B
Parasitology; 1986 Feb; 92 (Pt 1)():101-16. PubMed ID: 3083391
[TBL] [Abstract][Full Text] [Related]
38. Praziquantel-lipid nanocapsules: an oral nanotherapeutic with potential
Amara RO; Ramadan AA; El-Moslemany RM; Eissa MM; El-Azzouni MZ; El-Khordagui LK
Int J Nanomedicine; 2018; 13():4493-4505. PubMed ID: 30122922
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of treatment of murine Schistosoma mansoni infections with praziquantel and oxamniquine correlates with infection intensity: role of host antibody.
Fallon PG; Hamilton JV; Doenhoff MJ
Parasitology; 1995 Jul; 111 ( Pt 1)():59-66. PubMed ID: 7609991
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model.
Abla N; Keiser J; Vargas M; Reimers N; Haas H; Spangenberg T
PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005942. PubMed ID: 28934207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
